What is the appropriate starting dose and schedule for Abilify Maintena (aripiprazole) injection in a 16‑year‑old adolescent weighing 121 lb (≈55 kg)?

Abilify Maintena is NOT FDA-approved for adolescents under 18 years old

Do not initiate Abilify Maintena in this 16-year-old patient—the FDA-approved indication is for adults only, and you must first establish tolerability with oral aripiprazole for up to 2 weeks before considering any long-acting injectable formulation. 1

Critical FDA Labeling Restrictions

The FDA prescribing information for Abilify Maintena explicitly states:

• Approved for adults only for schizophrenia and bipolar I disorder maintenance 1
• No pediatric indication exists for the long-acting injectable formulation
• Mandatory tolerability testing: Patients who have never taken aripiprazole must establish tolerability with oral aripiprazole prior to initiating Abilify Maintena 1

If You Proceed Off-Label (Use Extreme Caution)

While the FDA label does not support use in adolescents, limited case reports suggest the following approach if you determine the clinical situation warrants off-label use:

Step 1: Establish Oral Tolerability First

• Start with oral aripiprazole 2-5 mg/day, titrating gradually to 10-30 mg/day over 1-2 weeks
• Monitor for at least 2 weeks due to aripiprazole's long half-life (75 hours for parent compound, 94 hours for active metabolite) 1
• Assess for extrapyramidal symptoms, akathisia, sedation, and metabolic effects

Step 2: If Tolerability Confirmed and LAI Deemed Necessary

Standard adult dosing is 400 mg monthly 1, but one adolescent case report used this dose successfully in a 16-year-old 2. The two initiation options per FDA labeling are:

Option A: 1-Day Initiation

• Two separate 400 mg IM injections in different sites (deltoid or gluteal, not same muscle)
• Plus one 20 mg oral aripiprazole dose on day 1
• This was successfully used in a 16-year-old case report 2

Option B: 14-Day Initiation

• One 400 mg IM injection
• Continue oral aripiprazole 10-20 mg daily for 14 consecutive days 1

Evidence from Adolescent Use

A 2022 case report described successful use of the two-injection start regimen in a 16-year-old with schizophrenia, showing good efficacy and tolerability with no akathisia or significant adverse effects 2. A 2025 study of 116 adolescents (mean age 16.17 years) using LAI antipsychotics including aripiprazole showed substantial improvement in mania scores, though weight gain was common (mean BMI increased from 23.4 to 26.3 kg/m²) 3.

Critical Safety Monitoring

• Weight and metabolic parameters: Monitor BMI, glucose, and lipids closely—adolescents may be particularly vulnerable to metabolic effects 3
• Extrapyramidal symptoms: While atypical antipsychotics theoretically have lower EPS risk, monitor for akathisia, dystonia, and tardive dyskinesia 4
• Functional outcomes: Track school attendance and social functioning as key quality-of-life markers 3

Common Pitfalls to Avoid

1. Skipping oral tolerability testing: The 2-week oral trial is non-negotiable—you cannot assess tolerability adequately in less time given aripiprazole's pharmacokinetics 1
2. Ignoring weight-based considerations: At 121 lbs (55 kg), this patient is smaller than typical adults; monitor closely for dose-related adverse effects
3. Failing to obtain informed consent: Parents/guardians must understand this is off-label use with limited pediatric safety data

Bottom Line

The safest and most appropriate approach is to use oral aripiprazole in this adolescent patient. If adherence concerns are severe enough to justify off-label LAI use despite lack of FDA approval, start with oral tolerability testing for 2 weeks minimum, then consider the 400 mg monthly dose using either initiation regimen, with intensive monitoring for metabolic and neurological adverse effects.